psalexa
logo

Bronchiectasis Therapeutics Pipeline Analysis 2017

Bronchiectasis Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: September 2017
Report Code: LS11178
Available Format:
Pages: 100

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Diagnosis

4.1.4 Treatment

4.1.5 Epidemiology

4.1.6 Unmet Needs

4.2 Key Drivers

4.2.1 Various Drug Designations from the USFDA

4.2.2 Technical Advancements

4.3 Key Barriers

4.3.1 Safety Concerns

4.4 Bronchiectasis Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Bronchiectasis Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed

5.1.1 ARD-3150

5.1.1.1 Clinical trial

5.1.1.2 Strategic development

5.1.1.3 Designation

5.2 Phase III

5.2.1 Ciprofloxacin Hydrochloride

5.2.1.1 Clinical trial

5.2.1.2 Strategic development

5.2.1.3 Designation

5.2.2 Colistimethate Sodium

5.2.2.1 Clinical trial

5.3 Phase II

5.3.1 Amikacin Liposome Inhalation Suspension

5.3.1.1 Clinical trial

5.3.1.2 Strategic development

5.3.1.3 Technology

5.3.2 Murepavadin

5.3.2.1 Clinical trial

5.3.2.2 Strategic development

5.3.2.3 Technology

5.3.3 Alpha-1 Proteinase Inhibitor (Human) Second Generation

5.3.3.1 Strategic development

5.3.3.2 Technology

5.4 Phase I

5.4.1 POL6014

5.4.1.1 Clinical trial

5.4.1.2 Strategic development

5.4.1.3 Technology

5.4.1.4 Financing

5.4.2 INS1007

5.4.2.1 Clinical trial

5.4.2.2 Strategic development

5.4.2.3 Designation

5.4.3 CHF6333

5.4.3.1 Clinical trial

5.4.4 AeroVanc

5.4.5 Molgramostim

5.4.5.1 Clinical trial

5.4.5.2 Strategic development

5.5 Pre-Clinical

5.5.1 Erdosteine

5.5.1.1 Strategic development

5.5.1.2 Technology

5.5.1.3 Designation

5.6 Unknown

5.6.1 Doxofylline

5.6.1.1 Strategic development

5.6.1.2 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Bronchiectasis Therapeutics Pipeline

7.2 SWOT Analysis of Bronchiectasis Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weakness

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 AstraZeneca PLC

8.1.1 Business overview

8.1.2 Product and service offerings

8.2 Bayer AG

8.2.1 Business overview

8.2.2 Product and service offerings

8.3 Aradigm Corporation

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 Insmed Incorporated

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Chiesi Farmaceutici S.p.A.

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 Alitair Pharmaceuticals, Inc.

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 Polyphor Ltd.

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 Zambon SpA

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 Kamada Ltd.

8.9.1 Business overview

8.9.2 Product and service offerings

8.10 Savara Inc.

8.10.1 Business overview

8.10.2 Product and service offerings

Chapter 9. Appendix

9.1 Abbreviations

 

LIST OF TABLES

 

TABLE 1: PIPELINE ANALYSIS OF BRONCHIECTASIS THERAPEUTICS, BY COMPANY (2017)

TABLE 2: DESCRIPTION OF ARD-3150

TABLE 3: CLINICAL TRIALS OF ARD-3150

TABLE 4: DESCRIPTION OF CIPROFLOXACIN HYDROCHLORIDE

TABLE 5: CLINICAL TRIALS OF CIPROFLOXACIN HYDROCHLORIDE

TABLE 6: DESCRIPTION OF COLISTIMETHATE SODIUM

TABLE 7: CLINICAL TRIALS OF COLISTIMETHATE SODIUM

TABLE 8: DESCRIPTION OF AMIKACIN LIPOSOME INHALATION SUSPENSION

TABLE 9: CLINICAL TRIALS OF AMIKACIN LIPOSOME INHALATION SUSPENSION

TABLE 10: DESCRIPTION OF MUREPAVADIN

TABLE 11: CLINICAL TRIALS OF MUREPAVADIN

TABLE 12: DESCRIPTION OF ALPHA-1 PROTEINASE INHIBITOR (HUMAN) SECOND GENERATION

TABLE 13: DESCRIPTION OF POL6014

TABLE 14: DESCRIPTION OF INS1007

TABLE 15: CLINICAL TRIALS OF INS1007

TABLE 16: DESCRIPTION OF CHF6333

TABLE 17: CLINICAL TRIALS OF CHF6333

TABLE 18: DESCRIPTION OF AEROVANC

TABLE 19: DESCRIPTION OF MOLGRAMOSTIM

TABLE 20: CLINICAL TRIALS OF MOLGRAMOSTIM

TABLE 21: DESCRIPTION OF ORAL ERDOSTEINE

TABLE 22: DESCRIPTION OF DOXOFYLLINE

TABLE 23: ASTRAZENECA PLC – AT A GLANCE

TABLE 24: BAYER AG – AT A GLANCE

TABLE 25: ARADIGM CORPORATION – AT A GLANCE

TABLE 26: INSMED INCORPORATED– AT A GLANCE

TABLE 27: CHIESI FARMACEUTICI S.P.A.– AT A GLANCE

TABLE 28: ALITAIR PHARMACEUTICALS, INC.– AT A GLANCE

TABLE 29: POLYPHOR LTD.– AT A GLANCE

TABLE 30: ZAMBON SPA – AT A GLANCE

TABLE 31: KAMADA LTD. – AT A GLANCE

TABLE 32: SAVARA INC.– AT A GLANCE

 

LIST OF FIGURES

 

FIG 1: RESEARCH METHODOLOGY FOR BRONCHIECTASIS THERAPEUTICS PIPELINE ANALYSIS

FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 4: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 5: BRONCHIECTASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

FIG 6: BRONCHIECTASIS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 7: BRONCHIECTASIS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 9: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 10: KEY PLAYERS BENCHMARKING

FIG 11: SWOT ANALYSIS

 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry